You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康樂衞士擬赴港上市,或將成為首家“北+H”兩地上市企業
格隆匯 12-27 09:02
北交所上市企業康樂衞士(833575.BJ)26日發佈公吿,計劃發行境外上市外資股(H股)並申請在港交所上市,這是繼今年6月29日北交所與港交所簽署合作備忘錄後,首家預備“北+H”兩地上市的企業。康樂衞士於今年3月15日登陸北交所,成為北交所人用疫苗第一股。12月11日,康樂衞士被納入北證50樣本股。公開資料顯示,康樂衞士是一家以基於結構的抗原設計為核心技術的生物醫藥企業,主要從事重組蛋白疫苗的研究、開發和產業化。公司重組三價HPV疫苗、重組九價HPV疫苗均已進入臨牀Ⅲ期,預計將分別於2024年和2025年提交生物製品許可申請(BLA)。此外,康樂衞士九價HPV疫苗是中國首家啟動男性適應症臨牀,且唯一處於Ⅲ期臨牀的國產HPV疫苗,預計於2027年提交BLA。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account